These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22975372)

  • 21. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
    Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
    J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
    Fonseca C; Soiffer R; Ho V; Vanneman M; Jinushi M; Ritz J; Neuberg D; Stone R; DeAngelo D; Dranoff G
    Blood; 2009 Feb; 113(8):1681-8. PubMed ID: 19008459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells.
    Tani K; Nakazaki Y; Hase H; Takahashi K; Azuma M; Ohata J; Kitamura R; Komine F; Oiwa M; Masunaga A; Maekawa T; Satoh N; Adachi D; Soda Y; Machida U; Endo M; Yamazaki T; Watari K; Tojo A; Yamashita N; Tomikawa S; Eriguchi M; Hamada H; Wakumoto Y; Hanazawa K; Okumura K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S73-6. PubMed ID: 10950152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
    Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
    Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular vaccine therapies for cancer.
    Mastrangelo MJ; Sato T; Lattime EC; Maguire HC; Berd D
    Cancer Treat Res; 1998; 94():35-50. PubMed ID: 9587681
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Bedke J; Stenzl A
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
    Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
    J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
    Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
    J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation peptide vaccines for advanced cancer.
    Yamada A; Sasada T; Noguchi M; Itoh K
    Cancer Sci; 2013 Jan; 104(1):15-21. PubMed ID: 23107418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of renal cell carcinoma.
    Gouttefangeas C; Stenzl A; Stevanović S; Rammensee HG
    Cancer Immunol Immunother; 2007 Jan; 56(1):117-28. PubMed ID: 16676181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
    Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
    Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring immune therapy for renal cancer.
    Matsushita H; Kakimi K; Tomita Y; Tatsugami K; Naito S; Suekane S; Noguchi M; Moriya F; Matsuoka K; Itoh K; Kobayashi H; Eto M; Takahashi W; Kawano Y; Wada Y
    Int J Urol; 2011 Jun; 18(6):412-21. PubMed ID: 21599759
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
    Yoshimura K; Minami T; Nozawa M; Uemura H
    Br J Cancer; 2013 Apr; 108(6):1260-6. PubMed ID: 23470466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status and future perspective of peptide vaccine for biliary tract cancer].
    Aruga A
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():823-6. PubMed ID: 25857143
    [No Abstract]   [Full Text] [Related]  

  • 38. Renal cell cancer: is immunotherapy dead?
    Wagstaff J
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
    [No Abstract]   [Full Text] [Related]  

  • 39. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications.
    Hoos A; Levey DL
    Expert Rev Vaccines; 2003 Jun; 2(3):369-79. PubMed ID: 12903802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.